CVS Health Corporation $CVS Shares Sold by Sachem Head Capital Management LP

Sachem Head Capital Management LP decreased its holdings in CVS Health Corporation (NYSE:CVS) by 17.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,585,000 shares of the pharmacy operator’s stock after selling 565,000 shares during the quarter. CVS Health accounts for approximately 4.8% of Sachem Head Capital Management LP’s holdings, making the stock its 12th largest position. Sachem Head Capital Management LP’s holdings in CVS Health were worth $205,146,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of CVS. Norges Bank bought a new position in shares of CVS Health in the fourth quarter worth $1,666,265,000. Wellington Management Group LLP grew its stake in shares of CVS Health by 391.6% in the third quarter. Wellington Management Group LLP now owns 6,330,717 shares of the pharmacy operator’s stock worth $477,273,000 after purchasing an additional 5,042,816 shares in the last quarter. Amundi grew its stake in shares of CVS Health by 95.3% in the third quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock worth $572,665,000 after purchasing an additional 3,637,943 shares in the last quarter. Capital Research Global Investors grew its stake in shares of CVS Health by 24.5% in the third quarter. Capital Research Global Investors now owns 11,469,250 shares of the pharmacy operator’s stock worth $864,667,000 after purchasing an additional 2,253,531 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its stake in shares of CVS Health by 70.5% in the third quarter. Arrowstreet Capital Limited Partnership now owns 5,294,134 shares of the pharmacy operator’s stock worth $399,125,000 after purchasing an additional 2,188,307 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding access to GLP-1 weight-loss drugs, including bringing back Zepbound and loosening restrictions on newer oral therapies, which could improve customer engagement and prescription volume while supporting its broader healthcare platform. Is CVS (CVS) Using GLP-1 Access and AI Tools to Redefine Its Healthcare Moat?
• Positive Sentiment: The company is also pushing AI deeper into pharmacy, insurance, and care delivery operations, aiming to cut administrative burden, improve efficiency, and potentially widen margins over time. Healthy Returns: CVS Health executives on reducing health care’s biggest pain points
• Positive Sentiment: CVS Health has launched Aetna Mental Health on Demand, which gives members faster access to care and shows the company is trying to strengthen service offerings across its insurance business. 5 Low Price-to-Book Stocks That Are Worth Buying in June
• Positive Sentiment: Recent coverage notes CVS at a 52-week high and highlights strong post-earnings momentum, while screening screens and “trending stock” mentions suggest investor interest remains elevated. CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?
• Neutral Sentiment: CVS is also working with Fluency to move autonomous AI agents from pilot projects into production, but the financial impact is still early and not yet quantified. CVS is Using Fluency to Close Enterprise AI Deployment Gap
• Neutral Sentiment: News that Mass General Brigham and CVS are moving closer to a primary care partnership and that the stock is being heavily discussed by retail investors adds attention, but these items are not immediate earnings drivers. Mass General Brigham and CVS primary care partnership moves closer to reality
• Negative Sentiment: Musab Balbale’s departure adds some leadership turnover, though the market may view it as a limited issue unless more executive changes follow. Musab Balbale Departs CVS Health

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CVS. Leerink Partners reissued an “outperform” rating and issued a $98.00 price target on shares of CVS Health in a research note on Thursday, March 5th. Wells Fargo & Company raised their target price on CVS Health from $102.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. TD Cowen raised their target price on CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Truist Financial raised their target price on CVS Health from $102.00 to $108.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a research note on Thursday. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $100.68.

CVS Health Trading Down 0.1%

NYSE:CVS opened at $101.87 on Monday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $102.77. The firm has a market capitalization of $129.98 billion, a price-to-earnings ratio of 44.88, a price-to-earnings-growth ratio of 1.00 and a beta of 0.62. The stock has a fifty day simple moving average of $86.91 and a 200 day simple moving average of $80.80.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The business had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same quarter last year, the company posted $2.25 EPS. CVS Health’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts forecast that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were given a $0.665 dividend. The ex-dividend date was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.6%. CVS Health’s dividend payout ratio (DPR) is 117.18%.

Insiders Place Their Bets

In related news, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the sale, the director directly owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,441,551 shares of company stock valued at $323,703,977 in the last quarter. 0.85% of the stock is currently owned by corporate insiders.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.